Synthesis and biological evaluation of novel amidinourea and triazine congeners as inhibitors of MDA-MB-231 human breast cancer cell proliferation

Daniele Castagnolo, Rosemary Bass, Sarah Jenkinson, Jennifer Wright, Tora Smulders-Srinivasan, Jamie Marshall

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)
2 Downloads (Pure)

Abstract

A series of novel amidinourea derivatives has been synthesised and the new compounds have been evaluated as inhibitors of MDA-MB-231 human breast cancer cell proliferation. In addition, a second series of triazine derivatives designed as rigid congeners of the amidinoureas was synthesised as well and the compounds were evaluated for their antiproliferative activity. Among the two series, the amidinourea 3d emerged as a potent anticancer hit compound with IC50 = 0.76 micormolar comparable to tamoxifen.
Original languageEnglish
JournalChemMedChem
Early online date11 Jan 2017
DOIs
Publication statusE-pub ahead of print - 11 Jan 2017

Fingerprint

Dive into the research topics of 'Synthesis and biological evaluation of novel amidinourea and triazine congeners as inhibitors of MDA-MB-231 human breast cancer cell proliferation'. Together they form a unique fingerprint.

Cite this